Keywords: کنگره آنتی بادی دارو; MW; molecular weight; MDR1; multiple drug resistance 1; P-gp; P-glycoprotein; ABC-transporter; ATP-binding cassette transporter; ATP; adenosine triphosphate; BBB; blood brain barrier; SLC transporter; solute carrier transporter; logP; partition coefficien
مقالات ISI کنگره آنتی بادی دارو (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugate; Hydrophilic interaction chromatography; High-resolution mass spectrometry; Post-translational modifications; Glycans profiling;
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugate; Binding kinetics parameters; Antitumor effects; Tumor penetration; Binding-site barrier; Tissue factor;
Determination of thiol-to-protein ratio and drug-to-antibody ratio by in-line size exclusion chromatography with post-column reaction
Keywords: کنگره آنتی بادی دارو; Ultra-high-performance liquid chromatography; DTNB; Post-column reaction; Monoclonal antibody; Antibody-drug conjugate; Process analytical technology;
Keywords: کنگره آنتی بادی دارو; Adoptive immunotherapy; Antibody-drug conjugate; Immune checkpoint inhibitor; Recombinant Bacillus Calmette-Guérin; Therapeutic cancer vaccine;
Keywords: کنگره آنتی بادی دارو; ABC; antibody-biologic conjugate; ADC; antibody-drug conjugate; ADCC; antibody-dependent cell-mediated cytotoxicity; ALL; acute lymphoblastic leukemia; ANC; antibody-nanoparticle conjugate; BBB; blood brain barrier; BiTE; bispecific T cell engager; CDC; c
Characterization of drug load variants in a thiol linked antibody-drug conjugate using multidimensional chromatography
Keywords: کنگره آنتی بادی دارو; ADC; antibody-drug conjugate; MS; mass spectrometry; PNGase F; peptide-N-glycosidase F; QTOF; quantitative time of flight; UV; ultraviolet; RP; reversed-phase liquid chromatography; nSEC; native size exclusion chromatography; nrRP; non-reduced reversed-ph
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugate; Albumin-drug conjugate; Prodrug; Glucuronide; Matrix metalloproteinase; Chemotherapy; Cancer; Tumor targeting;
Keywords: کنگره آنتی بادی دارو; stability; antibody-drug conjugate; immunoconjugate; degradation; aggregation; analytical; physicochemical; critical quality attribute;
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugate; Freeze-dried medicine; Moisture content; Near-infrared spectroscopy; Partial least squares regression; Validation;
Keywords: کنگره آنتی بادی دارو; Small cell lung cancer; Targeted therapies; Precision medicine; Molecular analysis; Angiogenesis; Cell signalling; Apoptosis; Immunotherapies; DNA repair; Antibody-drug conjugate;
Keywords: کنگره آنتی بادی دارو; Biotherapeutics; PEGylated biologics; Gene and cell therapy; Pharmacokinetics; Nonclinical safety; Antibody-drug conjugate; Immunogenicity; Cross-reactive species;
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugate; Oncology; ADCs; Immunoconjugate; Targeted therapy;
Keywords: کنگره آنتی بادی دارو; CD30; Reed-Sternberg; Monoclonal antibody; Antibody-drug conjugate;
Keywords: کنگره آنتی بادی دارو; Antibody; Native mass spectrometry; Glycan analysis; Antibody-drug conjugate; Q-TOF mass analyzer; Orbitrap mass analyzer;
Keywords: کنگره آنتی بادی دارو; AA; amino acid; UAA; unnatural amino acid; ADC; antibody-drug conjugate; DOPA; l-3,4-dihydroxyphenylalanine; flp; 4-(R)-fluoroproline; GnRH; gonadotropin-releasing hormone; hyp; hydroxyproline; LAR; long acting release; MOF; metal-organic framework; 4-D
Keywords: کنگره آنتی بادی دارو; ADC; antibody-drug conjugate; ADME; absorption, distribution, metabolism and elimination; EFD; embryofetal development; ELISA; enzyme-linked immunosorbent assay; FIH; first-in-human; GLP; Good Laboratory Practice; hERG; human ether-Ã -go-go related gene;
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugate; Combination therapy; Clinical trial; Ovarian cancer;
Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates
Keywords: کنگره آنتی بادی دارو; Malignant pleural mesothelioma; 5T4; Antibody-drug conjugate; Lysosome; treatment;
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target
Keywords: کنگره آنتی بادی دارو; GPNMB; Melanoma; Breast cancer; Invasion; Matrix metalloproteinase; Antibody-drug conjugate;
Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer
Keywords: کنگره آنتی بادی دارو; EGFR; epidermal growth factor receptor; IL-6; interleukin 6; ADC; antibody-drug conjugate; HGF; hepatocyte growth factor; c-met/MET; tyrosine-protein kinase Met; CTLA-4; cytotoxic T-lymphocyte-associated protein 4; VEGF; vascular endothelial growth factor
Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugates; Monoclonal antibodies; Anticancer; Drug resistance; Solid tumors; Hematological tumors; ADC; Antibody-Drug Conjugate; ALCL; Anaplastic Large Cell Lymphoma; ALL; Acute Lymphoblastic Leukemia; AML; Acute Myeloid Leukemia; BCMA; B C
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
Keywords: کنگره آنتی بادی دارو; Ovarian cancer; Antibody-drug conjugate; Clinical trial; Folate receptor alpha; Biopsy;
Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates
Keywords: کنگره آنتی بادی دارو; Cancer; Chemotherapy; Drug delivery; Self-immolative linker; Enzyme-responsive systems; Antibody-drug conjugate;
Comparison of SEC and CE-SDS methods for monitoring hinge fragmentation in IgG1 monoclonal antibodies
Keywords: کنگره آنتی بادی دارو; CE-SDS; SEC; Fragmentation; Antibody; Electrophoresis; IgG; immunoglobulin; HC; heavy chain; LC; light Chain; HL; heavy-light; HH; heavy-heavy; HHL; heavy-heavy-light; NGH; non-glycosylated heavy chain; LMW; low molecular weight; mAb; monoclonal antibody;
LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugate; Nano-surface and molecular-orientation limited (nSMOL) proteolysis; LC-MS; Bioanalysis; Liquid-liquid partition;
Synthesis and in vitro evaluation of SG3227, a pyrrolobenzodiazepine dimer antibody-drug conjugate payload based on sibiromycin
Keywords: کنگره آنتی بادی دارو; SG3227; Antibody-drug conjugate; Sibiromycin; Pyrrolobenzodiazepine dimer; DNA minor groove binding agent;
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
Keywords: کنگره آنتی بادی دارو; SYD985; T-DM1; Antibody-drug conjugate; Ovarian serous carcinoma; HER2; Ado-trastuzumab emtansine;
LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1)
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugate; T-DM1; LC-MS/MS; Catabolites;
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
Keywords: کنگره آنتی بادی دارو; ADC; antibody-drug conjugate; NHL; non-Hodgkin lymphoma; DLBCL; diffuse large B-cell lymphoma; ADCC; antibody-dependent cell-mediated cytotoxicity; CDC; complement-dependent cytotoxicity; MMAE; monomethyl auristatin E; SMCC; N-succinimidyl-4-(N-maleimidoe
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer
Keywords: کنگره آنتی بادی دارو; AE; Adverse Event; α-MSH; alpha-Melanocyte Stimulating Hormone; ADC; Antibody-Drug Conjugate; ASPS; Alveolar Soft Part Sarcoma; ASPSCR1; Alveolar Soft Part Sarcoma Chromosome Region Candidate 1; BMP-2; Bone Morphogenetic Protein-2; BRK; Breast Tumor Kina
Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas
Keywords: کنگره آنتی بادی دارو; 5FU; 5-fluorouracil; 95%CI; 95% confidence interval; α-SMA; α-smooth muscular actin; ADC; antibody-drug conjugate; ATP; adenosine triphosphate; BSC; best supportive care; CAF; cancer-associated fibroblast; CapIri; capecitabine plus irinotecan; CapOx; ca
Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy
Keywords: کنگره آنتی بادی دارو; EGFR; epidermal growth factor receptor; MMPs; matrix metalloproteinases; Ec; EGF derived oligopeptide; TIMP2; tissue inhibitor of matrix metalloproteinase 2; LDM; lidamycin; LDP; lidamycin apoprotein; AE; active enediyne; NSCLC; non-small-cell lung carcin
ReviewBrentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugate; Brentuximab vedotin; CD30; Hodgkin lymphoma; Named patient program;
Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin
Keywords: کنگره آنتی بادی دارو; 2-CdA; 2-chlorodeoxyadenosine; ADC; antibody-drug conjugate; ALCL; anaplastic large cell lymphoma; ANC; absolute neutrophil count; ASM; aggressive systemic mastocytosis; BM; bone marrow; CT; computed tomography; ECNM; European Competence Network on Mastoc
Impact of organic modifier and temperature on protein denaturation in hydrophobic interaction chromatography
Keywords: کنگره آنتی بادی دارو; Hydrophobic interaction chromatography; Monoclonal antibody; Antibody-drug conjugate; Organic modifier; Denaturation; Drug to antibody ratio
Characterization of therapeutic antibodies and related products by two-dimensional liquid chromatography coupled with UV absorbance and mass spectrometric detection
Keywords: کنگره آنتی بادی دارو; Protein; Biopharmaceutical; Monoclonal antibody; Antibody-drug conjugate; Two-dimensional liquid chromatography; Mass spectrometry;
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
Keywords: کنگره آنتی بادی دارو; ADC; antibody-drug conjugate; CI; combination index; CR; complete response; EOC; epithelial ovarian cancer; FRα; folate receptor alpha; PLD; pegylated liposomal doxorubicin;
Structural characterization of antibody drug conjugate by a combination of intact, middle-up and bottom-up techniques using sheathless capillary electrophoresis – Tandem mass spectrometry as nanoESI infusion platform and separation method
Keywords: کنگره آنتی بادی دارو; Sheathless capillary electrophoresis-mass spectrometry; Antibody-drug conjugate; vcMMAE-ADC; Drug to antibody ratio; Drug-loaded peptides
Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. II- Identification of sub-units for the characteri
Keywords: کنگره آنتی بادی دارو; On-line comprehensive 2DLC; HICxRPLC-QTOF-MS; Quadrupole time-of-flight; Antibody-drug conjugate; ADCs; Odd DARs;
Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine
Keywords: کنگره آنتی بادی دارو; Antibody-drug conjugate; Ado-trastuzumab emtansine; Two-dimensional liquid chromatography; Multiple heart-cutting; Comprehensive;
Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality
Keywords: کنگره آنتی بادی دارو; ADF; abuse deterrent formulation; API; active pharmaceutical ingredient; T-DM1; Ado-Trastuzumab Emtansine; ADC; antibody-drug conjugate; CDER; center for drug evaluation and research; CBRN/EID; chemical, biological, radiological/nuclear and emerging infec
Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives
Keywords: کنگره آنتی بادی دارو; Nanomedicine; Synergistic drug combinations; Cancer therapy; Strategies; Perspectives; ADC; antibody-drug conjugate; Akt; serine/threonine-specific protein kinase, or known as protein kinase B; BD; biodistribution; CI; combination index; cRGD Peptide; cyc
A simple LC/MRM-MS-based method to quantify free linker-payload in antibody-drug conjugate preparations
Keywords: کنگره آنتی بادی دارو; ADC; antibody drug conjugate; MRM; multiple-reaction monitoring; LLOQ; lower limit of quantification; DMSO; dimethyl sulfoxide; ACN; acetonitrile; RP-HPLC; reversed-phase high pressure liquid chromatography; TFF; tangential flow filtration; Antibody-drug
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Keywords: کنگره آنتی بادی دارو; Adult; Antibody-drug conjugate; CD19; Maytansine derivatives; Safety;
An FDA oncology analysis of antibody-drug conjugates
Keywords: کنگره آنتی بادی دارو; AD; acceptable dose; ADC; antibody-drug conjugate; ADCC; antibody-dependent cellular cytotoxicity; FIH; first-in-human; HNSTD; highest non-severely toxic dose; ICH; International Conference on Harmonization; LC/MS; liquid chromatography/mass spectrometry;
Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides
Keywords: کنگره آنتی بادی دارو; ADC; antibody-drug conjugate; MMAE; monomethyl-auristatin-E; PAB; p-aminobenzyloxy; mAb; monoclonal antibody; PEG; poly(ethylene glycol); MWCO; molecular weight cut-off; HPLC; high performance liquid chromatography; Q-TOF; Quadrupole-time-of-flight; RP-HP
Survey ReportEvaluation of genotoxicity testing of FDA approved large molecule therapeutics
Keywords: کنگره آنتی بادی دارو; Large molecule therapeutics; Biologics; Monoclonal antibodies; Peptides; Antibody-drug conjugate; Genetic toxicity studies; ICH S6(R1);
The past and future of CD33 as therapeutic target in acute myeloid leukemia
Keywords: کنگره آنتی بادی دارو; Acute myeloid leukemia; Antibody; Antibody-drug conjugate; Bispecific antibody; BiTE; CD33; Chimeric antigen receptor; Gemtuzumab ozogamicin; Immunotherapy; Radioimmunoconjugate
Treating the HER2 Pathway in Early and Advanced Breast Cancer
Keywords: کنگره آنتی بادی دارو; Human breast cancers; HER2 pathway; Antibody-drug conjugate;